Janssen-Cilag announced today that the trustees for Medicinal commodities for Human Use (CHMP) of the indo-european language Medicines Agency has decided to delay the italic language trust decision process on ZEVTERATM (ceftobiprole medocaril) pending completion of a Good Clinical exploit (GCP) inspection. ZEVTERA is in the final stage of commendation for the therapy of intricate skin and soft tissue infections.

More: - Brought to my attention by